Kwangdong Healthbio광동헬스바이오
086220 · KONEX · ₩086220 · 광동헬스바이오
₩1,179▼ ₩10 (0.84%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩67B | ₩66B | ₩80B | ₩64B | ₩58B |
| Cost of sales | ₩62B | ₩63B | ₩74B | ₩59B | ₩53B |
| Gross profit | ₩5.1B | ₩2.8B | ₩6.2B | ₩4.8B | ₩4.4B |
| Operating income | ₩900M | −₩996M | ₩2.6B | ₩1.6B | ₩848M |
| Net income | −₩641M | −₩2B | ₩570M | ₩701M | ₩438M |
| Net income to shareholders | −₩641M | −₩2B | ₩570M | ₩701M | ₩438M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩62B | ₩53B | ₩57B | ₩56B | ₩61B |
| Current assets | ₩27B | ₩16B | ₩19B | ₩15B | ₩19B |
| Cash and equivalents | ₩9.9B | ₩2.3B | ₩3.7B | ₩2.3B | ₩4.9B |
| Total liabilities | ₩44B | ₩37B | ₩39B | ₩38B | ₩44B |
| Current liabilities | ₩32B | ₩23B | ₩28B | ₩25B | ₩29B |
| Borrowings | ₩28B | ₩25B | ₩27B | ₩29B | ₩31B |
| Total equity | ₩18B | ₩16B | ₩18B | ₩18B | ₩17B |
| Shareholders' equity | ₩18B | ₩16B | ₩18B | ₩18B | ₩17B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩3.4B | ₩1.8B | ₩4B | ₩870M | ₩2.4B |
| Capital spending | ₩1.2B | ₩880M | ₩312M | ₩1.7B | ₩530M |
| Free cash flow | ₩2.1B | ₩879M | ₩3.7B | −₩806M | ₩1.9B |
Consolidated where available. Amounts in won.
Also known as: Kwangdong Healthbio / 광동헬스바이오 / 086220 / KRX:086220
Source: KRX statistical information